Document is current
Any future updates will be listed below
-
Authors
Chen, Xiaojing
Jin, Xitong
Kong, Linghua
Liou, Yuligh
Liu, Pei
Dong, Zhe
Zhou, Sijun
Qi, Bingli
Fei, Jing
Chen, Xiaoyan
Xiong, Guangwu
Hu, Yuchong
Liu, Shikai
Zhou, Jianwei
Shou, Huafeng
Li, Lei
-
Funding
Funding for this research was provided by:
State Key Laboratory for Complex, Severe and Rare Diseases in Peking Union Medical College Hospital, by the Beijing Science and Technology Projects (Z211100002921068)
the Key Research Project of Beijing Natural Science Foundation (Z220013)
the CAMS Innovation Fund for Medical Sciences (2022-I2M-C&T-B-033)
the National High Level Hospital Clinical Research Funding (2022-PUMCH-A-117, 2022-PUMCH-B-083, 2022-PUMCH-C-010, 2022-PUMCH-C-022 and 2022-PUMCH-D-003)
China Postdoctoral Science Foundation (2022T150066)
- License Information
-
More Information
Article History
Received: 27 February 2024
Accepted: 13 August 2024
First Online: 16 August 2024
Declarations
:
: The Institutional Review Board of Peking Union Medical College Hospital approved this study (No. JS-2380 and K-S2021211 for METHY3 and METHY4, respectively). The registration numbers are NCT04646954 and NCT05290428 (<i>clinicaltrials.gov</i>, registered on November 26, 2020, and March 12, 2022). Informed consent was obtained from the subjects prior to their participation in the study.
: The paper is not under consideration by another journal, and the results presented in this work have not been previously presented or published.
: Consent for publication has been obtained from all patients.
: The authors declare no competing interests.
